AlphaCrest Capital Management’s MillerKnoll MLKN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-172,362
Closed -$2.69M 706
2022
Q3
$2.69M Buy
172,362
+106,926
+163% +$2.94M 0.16% 131
2022
Q2
$1.72M Buy
65,436
+18,448
+39% +$559K 0.08% 401
2022
Q1
$1.62M Buy
46,988
+36,929
+367% +$1.36M 0.09% 326
2021
Q4
$394K Sell
10,059
-60,521
-86% -$2.36M 0.01% 1177
2021
Q3
$2.66M Buy
70,580
+52,969
+301% +$2.27M 0.14% 188
2021
Q2
$830K Sell
17,611
-15,068
-46% -$682K 0.04% 751
2021
Q1
$1.34M Buy
32,679
+12,862
+65% +$492K 0.08% 393
2020
Q4
$670K Sell
19,817
-16,838
-46% -$586K 0.06% 491
2020
Q3
$1.11M Buy
36,655
+18,102
+98% +$448K 0.12% 225
2020
Q2
$438K Sell
18,553
-49,717
-73% -$1.12M 0.07% 440
2020
Q1
$1.52M Buy
68,270
+50,617
+287% +$1.75M 0.18% 139
2019
Q4
$735K Buy
17,653
+2,453
+16% +$114K 0.06% 529
2019
Q3
$701K Sell
15,200
-13,800
-48% -$607K 0.04% 750
2019
Q2
$1.3M Sell
29,000
-1,000
-3% -$37.8K 0.11% 280
2019
Q1
$1.05M Buy
+30,000
New +$1.05M 0.16% 161

Other funds holding MLKN

AlphaCrest Capital Management's MLKN Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of MillerKnoll (MLKN) in Q4 2022, closing a stake of 172,362 shares — an estimated $2.69M sold.

AlphaCrest Capital Management first reported a position in MLKN in Q1 2019 and held it in 15 quarters. The position peaked at $2.69M in Q3 2022. 223 funds tracked by Wall St. Rank hold MLKN as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining MillerKnoll position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 172,362 MillerKnoll shares in Q4 2022, an estimated $2.69M.
  • AlphaCrest Capital Management first reported a position in MillerKnoll in Q1 2019 and held it in 15 quarters.
  • AlphaCrest Capital Management's MillerKnoll position peaked at $2.69M in Q3 2022.
  • 223 funds tracked by Wall St. Rank held MillerKnoll as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.